Research
Hormonal
Incretin-based therapies improve cardiovascular risk factors (lipids, blood pressure) and reduce the risk of major cardiovascular events and heart failure in individuals with obesity.
For those with obesity, incretin therapies like semaglutide offer cardiovascular protection, lowering risks of heart events and heart failure, independent of just weight loss.
StrongSupportsVERY_HIGH confidence
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly.
Why this rating
Supported by RCTs and the SELECT trial.
Source
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso et al. · npj Metabolic Health and Disease · 2024
DOI 10.1038/s44324-024-00030-5
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.Strong
- Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →